10-K: Quipt Home Medical to Go Private in $3.65/Share Deal

Quipt Home Medical Corp. reports a net loss for fiscal year 2025, impacted by Medicare reimbursement changes and a cybersecurity incident, while pursuing strategic acquisitions and a definitive take-private transaction.

Summary

• Net loss for the fiscal year ended September 30, 2025, was $10,701,000, an increase from $6,763,000 in 2024.
• Total revenues for the fiscal year ended September 30, 2025, decreased by 0.2% to $245,359,000 from $245,915,000 in 2024.
• Adjusted EBITDA for the fiscal year ended September 30, 2025, was $55,947,000, down from $57,746,000 in 2024.
• The company completed two acquisitions in fiscal year 2025: Mediserve Medical Equipment of Kingsport, Inc. for $2,616,000 and a 60% interest in IRB Medical Equipment, LLC (Hart) for $19,358,000 (consideration for controlling interest).
• The discontinuance of the Medicare 75/25 blended rate as of January 1, 2024, and the Change Healthcare cybersecurity incident negatively impacted revenue by an estimated $8,500,000 for the year ended September 30, 2025.
• A civil investigative demand (CID) from the Department of Justice (DOJ) is ongoing regarding potential false claims for CPAP equipment.
• The SEC concluded its investigation related to the DOJ CID and financial reporting in November 2024, advising no enforcement action.
• A definitive Arrangement Agreement was entered into on December 14, 2025, to be acquired by 1567208 B.C. Ltd. and REM Aggregator, LLC (Kingswood Capital Management, LP affiliates) for US$3.65 per share.
• The company's normal course issuer bid program expired on April 30, 2025, and was not renewed.

Sentiment

Score: 4

Explanation: The company reported increased net losses and decreased Adjusted EBITDA for the fiscal year, primarily due to external factors like Medicare reimbursement changes and a cybersecurity incident. While strategic acquisitions are ongoing and the SEC investigation concluded favorably, the definitive Arrangement Agreement to be acquired at $3.65 per share suggests a potential exit below prior market expectations, despite providing certainty to shareholders.

Positives

• Successfully completed two acquisitions, Mediserve Medical Equipment of Kingsport, Inc. and a 60% interest in Hart Medical Equipment, contributing to revenue growth in the fourth quarter of 2025.
• The SEC concluded its investigation into the company's financial reporting and DOJ CID without recommending enforcement action in November 2024.
• Strategic growth plan focuses on organic growth and expanding geographical footprint via synergistic acquisitions.
• Leveraging compliance technology to enhance patient compliance and streamline equipment delivery and setup.
• Positions itself as a solution to rising U.S. healthcare costs by offering more cost-effective home-based solutions.
• Gain on disposals of property and equipment increased to $1,225,000 for the year ended September 30, 2025, primarily from proceeds received from the return of recalled ventilators.
• Net cash flow provided by operating activities increased to $37,692,000 for the year ended September 30, 2025, from $35,381,000 in 2024.
• Maintained compliance with all financial covenants under its $110,000,000 senior credit facility as of September 30, 2025.

Negatives

• Net loss increased to $10,701,000 in fiscal year 2025 from $6,763,000 in 2024.
• Total revenues for fiscal year 2025 decreased slightly by 0.2% compared to 2024.
• Adjusted EBITDA decreased to $55,947,000 in fiscal year 2025 from $57,746,000 in 2024.
• The discontinuance of the Medicare 75/25 blended rate as of January 1, 2024, negatively impacted revenue and operating results by an estimated $8,500,000 for the year ended September 30, 2025.
• Experienced withdrawal of Medicare Advantage members due to a capitated agreement moving to other providers.
• A disposable supply contract was not renewed in November 2024.
• A cybersecurity incident at Change Healthcare (a third-party software provider) significantly impacted claims processing and cash flow during the three months ended March 31, 2024, and June 30, 2024, with continuing adverse effects into fiscal year 2025.
• Inventory sold as a percentage of revenue increased to 29.9% for the three months ended September 30, 2025, due to acquisitions and lower estimated vendor rebates.
• The normal course issuer bid program expired on April 30, 2025, and was not renewed, potentially impacting share valuation and liquidity.

Risks

• Reliance on relatively few suppliers for the majority of patient service equipment and supplies could adversely affect operations due to price increases or disruptions.
• Supply chain disruptions and economy-wide labor shortages in the U.S. have negatively impacted, and may continue to negatively impact, businesses and increase labor costs.
• Inflation and rising interest rates have had, and may continue to have, an adverse effect on costs and interest expense related to variable rate indebtedness.
• Dependence on information systems, including third-party software, poses risks of failure, significant disruption, cyber-attacks, security breaches, or improper disclosure/loss of data.
• Financial performance is affected by continuing efforts by private third-party payors to control costs, potentially leading to lower reimbursement rates.
• Payor contracts are subject to renegotiation or termination, which could result in a decrease in revenue or profits.
• Changes made by payors to the way they cover products supplied could have an adverse impact on revenue and operations.
• Changes in governmental or private payor supply replenishment schedules could adversely affect revenue.
• Failure to manage the complex and lengthy reimbursement process could cause revenue, financial condition, and results of operations to suffer.
• Consolidation among health insurers and other industry participants could adversely affect the ability to negotiate favorable terms.
• Inability to maintain current levels of collectability and deterioration of payors' financial condition, along with disputes with third parties, could negatively impact financial results.
• Inability to maintain or develop relationships with patient referral sources could adversely affect growth and profitability.
• Competition from numerous other sleep therapy equipment, home respiratory, and mobility equipment providers could adversely affect revenues and business.
• Changes in medical equipment technology and development of new treatments (e.g., GLP-1 receptor agonist drugs for obesity) may cause current equipment or services to become obsolete.
• Operations involve the transport of compressed and liquid oxygen, carrying inherent risks of rupture or other accidents and requiring significant compliance oversight and expenses.
• Outsourcing internal business functions to third-party providers (e.g., in India and the Philippines) carries significant risks, including disruptions, increased costs, and data security issues.
• Ability to successfully operate is largely dependent upon the efforts of key personnel, including senior management, the loss of whom could negatively impact operations and financial results.
• Strategic growth plan involving acquisitions may not succeed due to increased competition for candidates, integration difficulties, and failure to realize anticipated benefits.
• Political and economic conditions, including tariffs, natural disasters, and public health crises, could adversely affect revenue, financial condition, and results of operations.
• Current insurance program is expensive and may expose the company to unexpected costs or losses not covered by insurance.
• Potential conflicts of interest may arise for directors and officers.
• Conducts all operations through foreign subsidiaries in the US, making it dependent on their cash flows and exposed to foreign exchange risk (Canadian dollar holdings).
• Revenue could be impacted by federal and state changes to reimbursement and other Medicaid and Medicare policies, including the reinstatement of the 2% BDCA sequestration and the reversion of blended rates.
• Subject to US federal and state healthcare fraud and abuse and false claims laws and regulations, with an ongoing DOJ investigation regarding CPAP equipment claims.
• Failure to successfully design, modify, and implement technology-based and other process changes to maximize productivity and ensure compliance could negatively impact financial condition.
• If CMS requires prior authorization or implements changes in documentation necessary for products, revenue could be negatively impacted.
• Reimbursement claims are subject to audits by various governmental and private payor entities, which may negatively affect revenue and financial results.
• Significant reimbursement reductions and/or exclusion from markets or product lines could adversely affect the company due to competitive bidding programs.
• Failure to maintain required licenses, permits, and accreditation could impact operations.
• Legislative action or changes could adversely affect the business model, including potential government as exclusive provider or reduced Medicare/Medicaid funding.
• Healthcare reform legislation could have a material impact on business, results of operations, and financial condition.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws (e.g., HIPAA, HITECH Act, CCPA, CAN-SPAM Act, TCPA) could adversely affect business.
• Adverse effects from global climate change or legal, regulatory, or market responses to such change.
• If required to write down all or part of its goodwill ($61,560,000 as of September 30, 2025), net earnings and net worth could be materially adversely affected.
• May not be able to generate sufficient cash flow to cover required payments or comply with financial and operating covenants under long-term debt and operating leases.
• May need additional capital to fund operating subsidiaries and finance growth, which may not be obtainable on acceptable terms, or at all.
• Will continue to incur significantly increased expenses and administrative burdens as a public company, especially after ceasing to be an emerging growth company or smaller reporting company.
• Subject to risks associated with proxy contests and other actions of activist shareholders.
• May not be able to effectively maintain controls and procedures required by Section 404 of the Sarbanes-Oxley Act.
• Reduced disclosure requirements as an emerging growth company or smaller reporting company may make Common Shares less attractive to investors.
• Fluctuations in the price of securities could contribute to the loss of all or part of an investment.
• No current plans to pay cash dividends on Common Shares for the foreseeable future.
• Provisions in constating documents and under British Columbia law could make an acquisition more difficult and may prevent attempts by shareholders to replace or remove current management.
• Forward-looking statements may prove to be inaccurate, which could have a material adverse effect on business, financial condition, and results of operations.

Future Outlook

The company's priority remains the generation of operating profit, positive cash flow, and growth in Adjusted EBITDA for fiscal year 2026 and beyond. Plans include expanding in existing markets, leveraging business platforms to enter new markets, and broadening product offerings. Continued business integration, rationalization, and prior acquisitions are expected to drive revenue growth and profitability, with a focus on improving operational efficiencies and call center management.

Management Comments

• "Our priority continues to be the generation of operating profit, positive cash flow, and growth in Adjusted EBITDA, a non-GAAP financial measure which is defined below, in fiscal year 2026 and beyond."
• "As we continue to expand in our existing markets, we plan to leverage our business platforms to enter new markets and expand our product offerings."
• "Our continued business integration and rationalization, and our prior acquisitions, have given us a focus and path toward revenue growth and profitability."
• "We will continue to improve operational efficiencies and call center management as they are key execution points to maintaining our Adjusted EBITDA while growing revenues by cross selling products to existing and acquired patients."

Industry Context

The company operates in the U.S. durable medical equipment (DME) and home medical equipment (HME) market, specializing in respiratory diseases. It positions itself as a solution to rising healthcare costs by offering cost-effective home-based solutions. The industry is highly competitive, fragmented, and subject to significant regulatory scrutiny and changes in reimbursement policies from government (Medicare, Medicaid) and private payors. Consolidation among health insurers and the emergence of new treatments (e.g., GLP-1 drugs for obesity) are notable trends impacting demand and pricing. Cybersecurity threats, as evidenced by the Change Healthcare incident, pose a significant operational risk across the healthcare sector.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing investigation by the US Department of Justice (DOJ) concerning whether the company may have caused the submission of false claims to government healthcare programs for CPAP equipment.
• Company received a subpoena from the SEC in April 2024 related to the DOJ investigation and financial reporting; SEC concluded its investigation in November 2024 and did not intend to recommend enforcement action.

Related Party Transactions

• The company has six leases for office, warehouse, and retail space with a rental company affiliated with its Chief Executive Officer.
• Lease payments under these leases were approximately $65,000 per month for the twelve months ended September 30, 2025, with annual increases tied to the Consumer Price Index for All Urban Consumers (CPI-U) or 3%.
• One lease expires in June 2026, and the remaining five leases expire on September 30, 2029.

Stakeholder Impact

• Shareholders: Potential for a cash payment of US$3.65 per share if the acquisition by Kingswood Capital Management, LP affiliates closes, leading to de-listing and de-registration. Shareholders may exercise dissent rights. Options with an exercise price equal to or greater than US$3.65 will be cancelled for no consideration.
• Employees: Key personnel (CEO, CFO, CAO) have new employment agreements or retention bonuses. Employees of acquired companies (Mediserve, Hart) are integrated. Potential for severance payments for employees terminated without cause within one year following the acquisition of Hart.
• Customers/Patients: Continued provision of durable medical equipment and home medical equipment, with a focus on improving patient compliance through technology. Potential impact from changes in payor policies and the competitive landscape.
• Suppliers: Reliance on a few key suppliers poses risks of price increases or disruptions.
• Creditors: The company maintains compliance with financial covenants under its senior credit facility. The acquisition of Hart was funded by borrowings from this facility.

Next Steps

• Closing of the Arrangement Agreement with Kingswood Capital Management, LP affiliates during the first half of 2026.
• Upon completion of the acquisition, the company will become privately-held, de-listed from Nasdaq and TSX, and de-registered under the Securities Exchange Act of 1934.
• CMS will announce specific dates for registration and bidding for the next DMEPOS Competitive Bidding Program round in late spring/early summer 2026, with new payment rates in effect no later than January 1, 2028.
• The 2% BDCA sequestration cut will take effect in January 2026 and continue through 2032.
• Filing of the Proxy Statement for the 2026 Annual Meeting of Shareholders within 120 days of September 30, 2025.
• Continued focus on generating operating profit, positive cash flow, and growth in Adjusted EBITDA for fiscal year 2026 and beyond.
• Expansion in existing markets, entry into new markets, and broadening product offerings.
• Improvement of operational efficiencies and call center management.
• Ongoing cooperation with the DOJ investigation.

Key Dates

Recommendation

The company has entered into a definitive Arrangement Agreement to be acquired by Kingswood Capital Management, LP affiliates for US$3.65 per share. This fixed cash offer provides a clear exit for shareholders. Given the reported increased net losses, declining Adjusted EBITDA, and ongoing operational challenges (Medicare rate changes, cybersecurity incident impact), accepting the acquisition offer at a known price mitigates further market and operational risks. While the company has a growth strategy through acquisitions, the immediate certainty of the cash offer, especially in light of recent financial performance and industry headwinds, makes selling the recommended action for investors seeking to realize value from their holdings.

Keywords

Durable Medical Equipment, Home Medical Equipment, Respiratory Care, Sleep Apnea, Chronic Respiratory Failure, Oxygen Therapy, Healthcare Services, Acquisitions, SEC Filing, 10-K, Financial Results, Reimbursement, Cybersecurity, Merger, Kingswood Capital Management, Private Equity, Corporate Governance, Risk Factors, Executive Compensation